It appears as though the pharmaceutical juggernaut Eli Lilly is facing major legal backlash for failure to disclose discontinuation effects associated with their medication Cymbalta (Duloxetine). Cymbalta is an SNRI antidepressant that was approved in August 2004 for the treatment of major depression. A woman named Claudia Herrera has been making news headlines because she …
Oxaloacetate (or Oxaloacetic Acid) is an organic compound that is involved in many neurophysiological processes within your body. It plays a key role in functions such as: amino acid synthesis, citric acid cycle, fatty acid synthesis, gluconeogenesis, glyoxylate cycle, and the urea cycle. For example, oxaloacetate is considered an intermediate in the Kreb’s cycle prior …
Rexulti (Brexpiprazole) is a drug that was approved July 10, 2015 for the treatment of schizophrenia and as an adjunctive option for major depressive disorder. In clinical trials it was referred to as the chemical “OPC-34712” and is being marketed as a superior successor to Abilify (Aripiprazole) due to the fact that Abilify’s patent expired …
Depression is a growing epidemic that affects the lives of nearly 15 million Americans. The number of individuals diagnosed with depression will continue to grow as a result of population growth, poor diet, environmental toxins, genetic polymorphisms, and other unique neurophysiological factors. As a result of depression, it is estimated that nearly 1 out of …
A recent publication in the Journal of Psychiatric Practice documented that nearly 4/5 individuals diagnosed with major depression are considered ineligible to participate in clinical trials for new antidepressant drugs. This means that for every 5 individuals with depression that attempt to join an antidepressant clinical trial, only one will meet inclusion criteria for registration. …
Antipsychotics are drugs that alleviate symptoms of schizophrenia and psychotic episodes. These medications are considered highly effective interventions for mitigating “positive symptoms” such as hallucinations (e.g. hearing voices) and various types of delusions (e.g. assuming others are plotting against you). Approved uses for antipsychotics include treating individuals diagnosed with schizophrenia, bipolar disorder, and cases of …
Belsomra (Suvorexant) is a drug that was approved by the FDA in 2014 for the treatment of insomnia. It didn’t hit the market until 2015 and is regarded as the first of a new generation of sleeping pills called “orexin receptor antagonists.” Belsomra functions by binding to orexin (hypocretin) receptors OX1 and OX2 to inhibit …